Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade F 5.49 -0.90% -0.05
FENC closed down 0.9 percent on Wednesday, March 20, 2019, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical FENC trend table...

Date Alert Name Type % Chg
Mar 20 Calm After Storm Range Contraction 0.00%
Mar 20 Doji - Bullish? Reversal 0.00%
Mar 20 Lower Bollinger Band Walk Weakness 0.00%
Mar 20 Wide Bands Range Expansion 0.00%
Mar 20 Down 3 Days in a Row Weakness 0.00%
Mar 20 Down 4 Days in a Row Weakness 0.00%
Mar 20 Down 5 Days in a Row Weakness 0.00%
Mar 20 Lower Bollinger Band Touch Weakness 0.00%
Mar 20 Oversold Stochastic Weakness 0.00%
Mar 19 Calm After Storm Range Contraction -0.90%

Older signals for FENC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Biopharmaceutical Cancer Disease Oncology Brain Tumor Neuroblastoma Cancer Therapeutics Osteosarcoma Hearing Loss Localized Tumors Neoplasms
Is FENC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.99
52 Week Low 5.33
Average Volume 44,242
200-Day Moving Average 8.0263
50-Day Moving Average 6.784
20-Day Moving Average 6.494
10-Day Moving Average 6.083
Average True Range 0.3684
ADX 23.34
+DI 12.1699
-DI 32.8195
Chandelier Exit (Long, 3 ATRs ) 6.5372
Chandelier Exit (Short, 3 ATRs ) 6.4852
Upper Bollinger Band 7.5763
Lower Bollinger Band 5.4117
Percent B (%b) 0.04
BandWidth 33.332307
MACD Line -0.3429
MACD Signal Line -0.2047
MACD Histogram -0.1382
Fundamentals Value
Market Cap 86.55 Million
Num Shares 15.8 Million
EPS -0.29
Price-to-Earnings (P/E) Ratio -18.93
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.85
Resistance 3 (R3) 5.85 5.74 5.79
Resistance 2 (R2) 5.74 5.64 5.74 5.77
Resistance 1 (R1) 5.61 5.59 5.56 5.61 5.75
Pivot Point 5.50 5.50 5.47 5.50 5.50
Support 1 (S1) 5.37 5.40 5.32 5.37 5.23
Support 2 (S2) 5.26 5.35 5.26 5.21
Support 3 (S3) 5.13 5.26 5.19
Support 4 (S4) 5.13